Taiho Oncology, Inc. announced today that detailed results from the analysis of patients with prior gastrectomy enrolled in the Phase 3 TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine and tipiracil) in adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy, were published in the October 10, 2019 issue of JAMA Oncology.
A group of researchers from Hiroshima recently discovered the origin of a normal-looking stomach lining that covers sites of gastric cancer and makes it difficult to spot after the eradication of an H. pylori infection. H. pylori infection is a major cause of stomach cancer and causes inflammation by releasing substances that can destroy cells that line the stomach. This destruction and regeneration of tissue can lead to stomach cancer. This study found that even after treatment of the infection, H. pylori leaves behind layers of cells that seem normal but actually originate from stomach cancer tissue. Thus, clinicians should be aware of these layers as to not miss potential stomach cancer sites when treating patients who have been treated for H. pylori infection.
Stomach cancer should no longer be considered a disease only of older people, and patients under 40 with chronic digestive symptoms should be more actively investigated – especially if they are of Latin American ethnicity. This advice follows new data from a retrospective, observational study in Mexico which showed that one in seven of over 2,000 patients diagnosed with gastric cancer between 2004 and 2016 were under 40.
Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has approved LONSURF® as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
A double-blind phase 3 trial in Japan found that a combination of trifluridine and tipiracil significantly prolonged survival in patients with metastatic stomach cancer. These drugs improved overall survival compared to placebo regardless of gastrectomy. Results showed a 31 percent risk reduction of death which translates into an average increased survival time of 2.1 months compared to placebo.
UK researchers have recently launched a new clinical trial to develop a breath test that could help detect multiple cancer types. This technology could help doctors detect and diagnose cancers earlier by measuring volatile organic compounds (VOCs) through breath biopsy. Depending on conditions, cells can release different patterns of VOCs, and this trial sets out to evaluate if this tool can differentiate between patients with and without various cancer types.This trial will start off with patients with esophageal and stomach cancer and then expand to more cancer types, and is estimated to complete in December 2021.
Taiho Oncology announced that the FDA has granted priority review for the supplemental New Drug Application (sNDA) for LONSURF as new treatment for patients with previously treated advanced or metastatic gastric adenocarcinoma. The drug trial met its primary goal of prolonged overall survival and secondary endpoint measurements of progression-free survival (PFS) in addition to consistent safety and tolerability. LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidide phosphorylase inhibitor.
Helicobacter pylori, a specific strain of bacteria found more often in East Asian patients may be a risk factor for stomach cancer. Doctors want to identify who is most at risk for cancer carrying out a pilot study that would shape treatment and screening strategies for patients infected with this bacterium. Dr. Nina Salama considers that the global differences in stomach cancer risk can be partly attributed to differences in H. pylori itself. One way that H. pylori varies is in the CogA gene which encodes a toxin that helps the bacterium better attach to cells lining the stomach.